Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.
作者信息
Tam L-S, Li E K, Wong C-K, Lam C W K, Li W-C, Szeto C-C
出版信息
Ann Rheum Dis. 2006 Mar;65(3):417-8. doi: 10.1136/ard.2005.044248.
Abstract
摘要
相似文献
1
Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.
Ann Rheum Dis. 2006 Mar;65(3):417-8. doi: 10.1136/ard.2005.044248.
2
Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Lupus. 2008 Jul;17(7):638-44. doi: 10.1177/0961203308089408.
3
[Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial].
Zhonghua Nei Ke Za Zhi. 2005 Sep;44(9):672-6.
4
The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy.
Rheumatol Int. 2009 Sep;29(11):1331-5. doi: 10.1007/s00296-009-0861-3. Epub 2009 Jan 25.
5
Treatment of severe lupus nephritis: the new horizon.
Nat Rev Nephrol. 2015 Jan;11(1):46-61. doi: 10.1038/nrneph.2014.215. Epub 2014 Nov 25.
6
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Clin Rheumatol. 2019 Mar;38(3):859-867. doi: 10.1007/s10067-018-4348-z. Epub 2018 Nov 13.
7
The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.
PLoS One. 2015 Dec 15;10(12):e0144548. doi: 10.1371/journal.pone.0144548. eCollection 2015.
8
Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.
Semin Nephrol. 2015 Sep;35(5):509-20. doi: 10.1016/j.semnephrol.2015.08.012.
9
Treatment of Crohn's disease with leflunomide as second-line immunosuppression : a phase 1 open-label trial on efficacy, tolerability and safety.
Dig Dis Sci. 2008 Apr;53(4):1025-32. doi: 10.1007/s10620-007-9953-7. Epub 2007 Oct 13.
10
Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.
Clin Rheumatol. 2019 Apr;38(4):1047-1054. doi: 10.1007/s10067-018-4368-8. Epub 2018 Nov 28.
引用本文的文献
1
Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.
Signal Transduct Target Ther. 2025 Mar 17;10(1):102. doi: 10.1038/s41392-025-02168-0.
2
II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.
Adv Rheumatol. 2024 Jun 18;64(1):48. doi: 10.1186/s42358-024-00386-8.
3
Treatment of refractory lupus nephritis using leflunomide: A prospective study.
Front Immunol. 2023 Mar 17;14:1133183. doi: 10.3389/fimmu.2023.1133183. eCollection 2023.
4
Expert Perspective: An Approach to Refractory Lupus Nephritis.
Arthritis Rheumatol. 2022 Jun;74(6):915-926. doi: 10.1002/art.42092. Epub 2022 Apr 25.
5
Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus.
JCI Insight. 2020 Feb 27;5(4):122312. doi: 10.1172/jci.insight.122312.
6
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.
Nat Rev Rheumatol. 2020 Jan;16(1):32-52. doi: 10.1038/s41584-019-0337-0. Epub 2019 Dec 12.
7
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.
Drugs R D. 2019 Dec;19(4):351-366. doi: 10.1007/s40268-019-00286-z.
8
Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.
Clin Rheumatol. 2019 Apr;38(4):1047-1054. doi: 10.1007/s10067-018-4368-8. Epub 2018 Nov 28.
9
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Clin Rheumatol. 2019 Mar;38(3):859-867. doi: 10.1007/s10067-018-4348-z. Epub 2018 Nov 13.
10
Current status of lupus nephritis.
Indian J Med Res. 2017 Feb;145(2):167-178. doi: 10.4103/ijmr.IJMR_163_16.
本文引用的文献
1
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
Arthritis Rheum. 1997 Sep;40(9):1725. doi: 10.1002/art.1780400928.
2
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.
Arthritis Rheum. 1992 Jun;35(6):630-40. doi: 10.1002/art.1780350606.
Zotero 插件